	US 12,371,491 B2
	Anti-TIGIT immunosuppressant and application thereof
Junjie Huang, Guangzhou (CN); Xiaoyun Wu, Guangzhou (CN); Zhenqian Xu, Guangzhou (CN); Shide Liang, Guangzhou (CN); Shengfeng Li, Guangzhou (CN); Jin-Chen Yu, Guangzhou (CN); and Xianming Huang, Guangzhou (CN)
Assigned to Bio-Thera Solutions, Ltd., Guangzhou (CN)
Appl. No. 17/639,877
Filed by Bio-Thera Solutions, Ltd., Guangdong (CN)
PCT Filed Sep. 3, 2020, PCT No. PCT/CN2020/113200 § 371(c)(1), (2) Date Mar. 2, 2022, PCT Pub. No. WO2021/043206, PCT Pub. Date Mar. 11, 2021.
Claims priority of application No. PCT/CN2019/104258 (WO), filed on Sep. 3, 2019.
Prior Publication US 2022/0348650 A1, Nov. 3, 2022
Int. Cl. C07K 16/00 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01)

CPC C07K 16/2803 (2013.01) [A61P 35/00 (2018.01); C07K 2317/24 (2013.01); C07K 2317/515 (2013.01); C07K 2317/52 (2013.01); C07K 2317/732 (2013.01); C07K 2317/92 (2013.01)]

16 Claims

1. An antibody or a fragment thereof specifically binding to a T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains (TIGIT), wherein the antibody or the fragment thereof comprises a VH CDR1 set forth in SEQ ID NO: 21, a VH CDR2 set forth in SEQ ID NO: 22, a VH CDR3 set forth in SEQ ID NO: 23, a VL CDR1 set forth in SEQ ID NO: 25, a VL CDR2 set forth in SEQ ID NO: 26 or 43, and a VL CDR3 set forth in SEQ ID NO: 27.